Agenda:
AOSD and sJIA are Still’s disease with different time of onset. However, no consistent and standardized treatment has been established for Still’s disease. The purpose of session is deepening the understanding of the latest treatment of AOSD and sJIA in Japan and Europe, to disseminate the optimal treatment of Still’s disease, mainly for Japanese adult rheumatologists.
|
|
Chairperson: Prof. Yuko Kaneko
|
|
11:10-12:15 |
The role of CANAKINUMAB in the Still’s disease treatment paradigm
Prof. Lorenzo Dagna |
